IRCT20171118037528N1.

Trial name or title	Acronym: —
Methods	Type of trial: efficacy trial Allocation: randomised Intervention model: parallel assignment Masking: double‐blinded (participants and administrators) Primary purpose: treatment
Participants	Condition: type 2 diabetes mellitus Enrolment: estimated 72 Inclusion criteria Patients with type 2 diabetes who have been diagnosed for at least 3 months 30 to 60 years of age BMI 24 to 30 kg/m² Exclusion criteria Clinical diagnosis of any liver, kidney, cancer, or Alzheimer disease Insulin therapy HbA1c = 8% Consumption of any anti‐oxidant supplements in the last 6 months History of allergic reaction to grapes Consumption of anti‐coagulants Fibrates and aspirin Drinking red wine and alcohol History of myocardial infraction Presence of stent or battery in the heart Gastrointestinal ulcer Pregnancy or lactation Following the unusual diet until 1 month before the study Unwillingness to participate in the study
Interventions	Intervention(s): resveratrol (500 mg oral 2 times a day) Comparator(s): placebo capsules
Outcomes	Primary outcome(s): peroxisome proliferator‐activated receptor alpha, p53 gene, p21 gene, p16 gene, soluble cluster of differentiation 163, TNF‐related weak inducer of apoptosis Secondary outcome(s): total triglycerides, total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, fasting blood glucose, glycated haemoglobin, fasting insulin Other outcome(s): —
Starting date	Trial start date: July 2018 Trial completion date: not reported
Contact information	Responsible party/principal investigator: Shima Abdollahi, Shahid Sadoughi University of Medical Science
Study identifier	Trial identifier:IRCT20171118037528N1
Official title	Effects of resveratrol on lipid and glycemic profile indices, expression of PPARα, some factors associated with cell cycle arrest and sCD163 to sTWEAK ratio in T2DM patients
Stated purpose of study	Quote: "effects of resveratrol on lipid and glycemic profile indices, expression of PPARα, some factors associated with cell cycle arrest and sCD163 to sTWEAK ratio in T2DM patients"
Notes